Abstract
Introduction: Neoadjuvant radiochemotherapy (RT/CTx) regimens were primarily designed for treatment of squamous cell carcinoma (SCC) of the esophagus. Own results demonstrate that also patients with locally advanced adenocarcinoma (AC) of the esophagus may achieve a major response in 30 % with a 3 year survival rate of 80 %. To identify these patients, ERCC1 (rs11615) gene polymorphisms were analyzed. ERCC1 is a key enzyme of the nucleotide excision and repair (NER) complex to prevent DNA inter- and intrastrand crosslinks. Methods: Genomic DNA from 144 patients with adenocarcinoma of the esophagus was extracted from paraffin-embedded tissues. For analysis of ERCC1 single nucleotide polymorphisms (SNPs) allelic discrimination was performed by quantitative realtime PCR. Two allele-specific TaqMan probes in competition were used for amplification of ERCC1 (rs11615). Allelic genotyping was correlated with histomorphologic tumor regression and survival after neoadjuvant RT/CTx. Major response (MaHR) was defined as ≤ 10 % vital residual tumor cells. Results: Analysis of tumor regression revealed a MaHR in 49/144 (34 %) patients with a 5-year survival rate (5-YSR) of 72 % (p = 0.0001). ERCC1 gene polymorphisms for all patients showed the following expression pattern: ERCC1 polymorphism (rs11615) CC: n = 13 (9 %), TT: n = 74 (51 %), CT: n = 57 (40 %). ERCC1 polymorphism CT was identified as a predictor for response to the neoadjuvant RT/CTx (p < 0.001). The 5-YSR for patients with CT genotype was 53 %. Contrary to this, the 5-YSR for the group of patients with a CC/TT-polymorphism decreased to 33 %. Conclusion: Analysis of ERCC1 (rs11615) gene polymorphisms reveals a significant (p < 0.001) correlation with response and survival in patients with adenocarcinoma of the esophagus treated with a neoadjuvant radiochemotherapy (CDDP, 5-FU, 36Gy). Single nucleotide polymorphisms of ERCC1 (rs11615) could therefore be applied to further individualize therapy in esophageal cancer.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsLiteratur
Gossage L, Madhusudan S. (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treatment Rev 33: 565–577
Bollschweiler E, Metzger R, Drebber U et al. (2009) Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis, Ann Oncol 12: 1815—1821
Warnecke-Eberz U, Metzger R, Drebber U, et al. (2004) High specifity of quantitative excisison repair cross-complementing 1 messenger RNA-expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 10: 3794–3799
Warnecke-Eberz U, Vallböhmer, Alakus et al. (2009) ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant RT/CTx in esophageal cancer. J Gastrointest Surg 13: 1411–1421
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Metzger, R. et al. (2010). ERCC1 Gen-Polymorphismus zur Responseund Prognoseprädiktion einer neoadjuvanten Radiochemotherapie beim Adenocarcinom des Ösophagus. In: Gradinger, R., Menger, M., Meyer, HJ. (eds) Chirurgisches Forum und DGAV Forum 2010. Deutsche Gesellschaft für Chirurgie, vol 39. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12192-0_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-12192-0_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-12191-3
Online ISBN: 978-3-642-12192-0
eBook Packages: Medicine (German Language)